• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

COVID-19 scenario and recommendations on the continuity of immunobiological therapy in patients with atopic asthma in Brazil and Latin America
Expert Rev Respir Med. 2022 Jan 17. doi: 10.1080/17476348.2022.2027758. Online ahead of print.ABSTRACTINTRODUCTION: With the abrupt establishment of the COVID-19 pandemic, treatment for immunological diseases may be influenced by the SARS-CoV-2 infection, including asthma and other allergies. Immunobiologics play a pivotal role in the management of severe symptoms of allergy and an opinion regarding the continuity of this treatment during the COVID-19 pandemic must be issued.AREAS COVERED: In Brazil and other countries, patients with severe asthma were included in the priority groups for COVID-19 vaccination, even those wh...
Source: Expert Review of Respiratory Medicine - January 17, 2022 Category: Respiratory Medicine Authors: Rafael de Oliveira Resende Vin ícius José de Oliveira Alessandro Sousa Correa Pedro Trica de Ara újo Ernesto Akio Taketomi Source Type: research

Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this management. ...
Source: JEMS Patient Care - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Pfizer/BioNTech ’s COVID-19 Vaccine Gets a Major Endorsement from FDA Committee
In a 17-4 vote (with one abstention) the U.S. Food and Drug Administration’s (FDA) vaccine advisory committee recommended that Pfizer/BioNTech’s COVID-19 vaccine should be distributed to the American public. With that recommendation hand, an FDA team led by the agency’s commissioner Dr. Stephen Hahn will now make a final decision about whether to issue an emergency use authorization (EUA) for the vaccine for anyone 16 years and older. The committee vote is not binding, but the agency is likely follow its advice, especially given the urgent need for a vaccine to stave off a rising tide of new infections. T...
Source: TIME: Health - December 11, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

The First Authorized COVID-19 Vaccine in the U.S. Has Arrived
Late in the evening on Dec. 11, the U.S. Food and Drug Administration (FDA) authorized the first COVID-19 vaccine for use in the country. The emergency use authorization means that doses of the vaccine—made by Pfizer/BioNTech—can be shipped at any time; certain Americans could be vaccinated as soon as next week. In a statement, FDA commissioner Dr. Stephen Hahn said “The FDA’s authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world.” In the same pr...
Source: TIME: Health - December 11, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news